Patents by Inventor David Stojdl

David Stojdl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220305099
    Abstract: Provided herein is a method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a priming composition comprising a peptide antigen conjugate and at least a first boost. The first boost comprises a first oncolytic virus comprising a genome that expresses a first peptide or a second peptide, wherein the first and second peptide are each capable of inducing an immune response to at least one neoantigen. The method further comprises administering the subject a second boost, comprising a second oncolytic virus comprising a genome that expresses a third peptide or a fourth peptide, wherein the third peptide and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 29, 2022
    Applicant: TURNSTONE BIOLOGICS CORP.
    Inventors: David STOJDL, Geoffrey Martin LYNN, Andrew Scott ISHIZUKA
  • Publication number: 20220160800
    Abstract: In one aspect, provided herein is a heterologous boost method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a first boost and subsequently administering to the subject a second boost, wherein the first boost comprises a first oncolytic virus comprising a genome that expresses, in the subject, a first peptide, or the first boost comprises a first oncolytic virus and a second peptide, wherein the second boost comprises a second oncolytic virus comprising a genome that expresses, in the subject, a third peptide, or the second boost comprises a second oncolytic virus and a fourth peptide, wherein the first peptide, the second peptide, the third peptide, and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 26, 2022
    Applicants: TURNSTONE BIOLOGICS INC., CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
    Inventors: David Stojdl, Justyna KMIECIK, Michael F. BURGESS
  • Publication number: 20220152168
    Abstract: The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Applicants: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., TURNSTONE BIOLOGICS INC.
    Inventors: David Stojdl, Justyna KMIECIK, Michael F. BURGESS
  • Publication number: 20150307559
    Abstract: Described herein is an isolated viral particle having a genome that includes open reading frames that encode: Maraba proteins N, P, and L, or variants thereof; as well as Maraba protein M or protein delta 51M, or variants thereof; and a Bahia Grande G protein, a LCMV G protein, or an Ebola G protein. Maraba protein N may have a sequence which includes SEQ ID NO: 1. Maraba protein P may have a sequence which includes SEQ ID NO: 2. Maraba protein L may have a sequence which includes SEQ ID NO: 3. Maraba proteins M and delta 1M may have sequence which include SEQ ID NO: 4 and 5, respectively. Bahia Grande G protein may have a sequence which includes SEQ ID NO: 6. LCMV G protein may have a sequence which includes SEQ ID NO: 7. Ebola G protein may have a sequence which includes SEQ ID NO: 8.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 29, 2015
    Inventors: David STOJDL, John Cameron BELL
  • Patent number: 8481023
    Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: July 9, 2013
    Assignee: Ottawa Hospital Research Institute
    Inventors: David Stojdl, Christopher Brown, John Bell
  • Publication number: 20110052539
    Abstract: Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
    Type: Application
    Filed: September 17, 2007
    Publication date: March 3, 2011
    Inventors: David Stojdl, Christopher Brown, John Bell
  • Publication number: 20100266618
    Abstract: Disclosed are compositions and methods for augmenting activity of oncolytic viruses. Virus activity is augmented by sensitizing cancer or tumour cells through modulation of the Endoplasmic Reticulum (ER) stress response pathway, for instance by introducing into a tumour cell an agent effective to modulate ER stress response and sensitize the tumour cell. The tumour cells are then contacted with an oncolytic virus in an amount effective to reduce viability of the sensitized tumour cell. The oncolytic virus is thereby rendered more effective at lysing or killing the sensitized tumour or cancer cells.
    Type: Application
    Filed: March 18, 2010
    Publication date: October 21, 2010
    Applicant: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE
    Inventors: David Stojdl, Douglas Mahoney
  • Publication number: 20070166287
    Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
    Type: Application
    Filed: March 13, 2007
    Publication date: July 19, 2007
    Applicant: WELLSTAT BIOLOGICS CORPORATION
    Inventors: John Bell, Nahum Sonenberg, David Stojdl, Earl Brown, Harold Atkins, Ricardo Marius, Brian Lichty, Shane Knowles
  • Publication number: 20070141033
    Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 21, 2007
    Applicants: WELLSTAT BIOLOGICS CORPORATION, UNIVERSITY OF OTTAWA
    Inventors: Harold Atkins, John Bell, Conrad Heilman, Brian Lichty, Robert Lorence, Michael Roberts, David Stojdl